Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

3.7%

1 terminated/withdrawn out of 27 trials

Success Rate

93.8%

+7.2% vs industry average

Late-Stage Pipeline

33%

9 trials in Phase 3/4

Results Transparency

20%

3 of 15 completed trials have results

Key Signals

3 with results

Enrollment Performance

Analytics

N/A

5(27.8%)

Phase 3

5(27.8%)

Phase 4

4(22.2%)

Phase 2

3(16.7%)

Phase 1

1(5.6%)

18Total

N/A(5)

Phase 3(5)

Phase 4(4)

Phase 2(3)

+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (27)

Showing 20 of 27 trials

NCT03256422Phase 3Completed

Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients

Role: collaborator

NCT07402044Not Yet Recruiting

CABOTEGRAVIR/LENACAPAVIR DUAL LONG ACTING THERAPY (COHORT IMEA 074)

Role: lead

NCT06657885Phase 2Withdrawn

CAbotégravir LENacapavir DUal Long Acting

Role: lead

NCT07122557Not Yet Recruiting

Real World Effectiveness of Bictegravir/Emtricitabine/Tenofovir Alafenamide(BIC/FTC/TAF) in PLWH in Precarity Settings in France -IMEA073

Role: lead

NCT06289361Active Not Recruiting

Cohort IMEA 070 -Lenacapavir Compassional

Role: lead

NCT06656611Not ApplicableNot Yet Recruiting

Mobile Outreach Screening of High-Risk Human Papillomavirus Infection in Women with Limited Access to Health Services in Seine-Saint-Denis (greater Paris Area, France)

Role: lead

NCT06649396Not ApplicableNot Yet Recruiting

Determination of New Detection and Quantification Thresholds for Serological and Molecular Tests for Hepatitis Delta Virus (HDV) Using Capillary Blood on Blotting Paper (DBS)

Role: lead

NCT05581160Not ApplicableCompleted

Assess the Performance of Metagenomic Sequencing in the Diagnosis of STI (NGS-IST)

Role: lead

NCT05761509Completed

"Observational Study on Tolerability and Observance of Post-exposure Prophylaxis With Doravirine in HIV Viral Risk"

Role: lead

NCT03767374Completed

Risk-factors for Multidrug-resistant Bacteria Colonization Among Patients at High Risk of STIs

Role: lead

NCT04993872Phase 4Unknown

Pharmacokinetics of Calcineurin & mTOR Inhibitors in HIV-1 Infected Kidney Transplant Recipients After Switch to BIC/FTC/TAF

Role: lead

NCT05415930Unknown

Evaluation of an Adaptative, Multidisciplinary, Reach-out Program, Facilitating Pre Exposition HIV Prophylaxis (PrEP) Prescription and Retention in Care, in a Group of Trans Womens (TW) at High Risk of HIV Infection.

Role: lead

NCT04222283Phase 4Unknown

Switch to TAF+FTC+BIC in HIV-1-infected Patients Over 65 Years Old at Risk of Polymedication

Role: lead

NCT02886624Phase 2Completed

Short Duration Therapy of Acute Hepatitis C Genotypes 1 or 4

Role: lead

NCT03858478Phase 4Unknown

Initiation of First-line Antiretroviral Treatment With TENOFOVIR ALAFENAMIDE - EMTRICITABINE - BICTEGRAVIR at the First Clinical Contact in France: Trial IMEA 055 - FAST

Role: lead

NCT02976259Phase 3Completed

Kinetics of HIV-RNA Decay in Seminal Plasma of Men Treated by Dolutegravir at the Time of Primary HIV Infection

Role: lead

NCT02889094Unknown

French HIV-HBV Cohort

Role: lead

NCT01928407Phase 4Completed

Evaluation of the Efficacy and Safety Between Two Antiretroviral Regimens, in HIV-1-infected Treatment-naïve Subjects With Low CD4 Counts

Role: lead

NCT02571959Phase 1Completed

Pharmacokinetic Study of the Association of Amoxicillin / Clavulanic Acid to Obese Adults